Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera.

Lescuyer S, Ledoux MP, Gravier S, Natarajan-Amé S, Duval C, Maloisel F, Mauvieux L, Toussaint E, Fornecker LM, Herbrecht R.

Int J Infect Dis. 2019 Mar;80:134-136. doi: 10.1016/j.ijid.2019.01.002. Epub 2019 Jan 11.

2.

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.

Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, Karim Z, Puy H, Alary AS, Ducamp S, Verdier F, Bouilloux C, Rousseau A, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Amé S, Rose C, Lachenal F, Toma A, Pica GM, Carre M, Garban F, Mariette C, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Dreyfus F, Fontenay M.

Haematologica. 2019 Mar;104(3):497-504. doi: 10.3324/haematol.2018.203158. Epub 2018 Oct 4.

3.

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F.

Leukemia. 2018 Aug;32(8):1768-1777. doi: 10.1038/s41375-018-0210-1. Epub 2018 Jul 20.

4.

History and Outcome of Febrile Neutropenia Outside the Oncology Setting: A Retrospective Study of 76 Cases Related to Non-Chemotherapy Drugs.

Andrès E, Mourot-Cottet R, Maloisel F, Keller O, Vogel T, Séverac F, Tebacher M, Gottenberg JE, Weber JC, Kaltenbach G, Goichot B, Sibilia J, Korganow AS, Herbrecht R.

J Clin Med. 2017 Sep 26;6(10). pii: E92. doi: 10.3390/jcm6100092.

5.

History and outcome of febrile neutropenia related to non-chemotherapy drugs: A retrospective study of the Strasbourg's agranulocytosis cohort.

Andrès E, Mourot-Cottet R, Maloisel F, Vogel T, Tebacher M, Gottenberg JE.

Eur J Intern Med. 2017 Dec;46:e13-e14. doi: 10.1016/j.ejim.2017.08.018. Epub 2017 Aug 18. No abstract available.

PMID:
28823525
6.

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.

Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, Guilhot J, Rousselot P, Huguet F, Legros L, Gardembas M, Dubruille V, Guerci-Bresler A, Charbonnier A, Maloisel F, Ianotto JC, Villemagne B, Mahon FX, Moins-Teisserenc H, Dulphy N, Toubert A.

Haematologica. 2017 Aug;102(8):1368-1377. doi: 10.3324/haematol.2017.165001. Epub 2017 May 18.

7.

Idiosyncratic drug-induced neutropenia & agranulocytosis.

Andrès E, Mourot-Cottet R, Maloisel F, Séverac F, Keller O, Vogel T, Tebacher M, Weber JC, Kaltenbach G, Gottenberg JE, Goichot B, Sibilia J, Korganow AS, Herbrecht R.

QJM. 2017 Jan 9. pii: hcw220. doi: 10.1093/qjmed/hcw220. [Epub ahead of print]

PMID:
28069912
8.

Idiosyncratic Drug-Induced Severe Neutropenia and Agranulocytosis in Elderly Patients (≥75 years): A Monocentric Cohort Study of 61 Cases.

Mourot-Cottet R, Maloisel F, Séverac F, Keller O, Vogel T, Tebacher M, Weber JC, Kaltenbach G, Gottenberg JE, Goichot B, Sibilia J, Korganow AS, Herbrecht R, Andrès E.

Drugs Real World Outcomes. 2016 Dec;3(4):393-399.

9.

Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study.

Etienne G, Huguet F, Guerci-Bresler A, Nicolini FE, Maloisel F, Coiteux V, Dauriac C, Carpentier N, Bourdeix I, Tulliez M, Cony-Makhoul P.

Br J Haematol. 2016 Jul;174(1):71-80. doi: 10.1111/bjh.14022. Epub 2016 Apr 7.

PMID:
27060881
10.

Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis.

Herbaux C, Duployez N, Badens C, Poret N, Gardin C, Decamp M, Eclache V, Daliphard S, Murati A, Cony-Makhoul P, Cheze S, Beve B, Lacoste C, Prebet T, Hunault-Berger M, Maloisel F, Renneville A, Figeac M, Stamatoullas-Bastard A, Bastard C, Fenaux P, Preudhomme C, Rose C; GFM (Groupe Francophone des Myelodysplasies).

Am J Hematol. 2015 Aug;90(8):737-8. doi: 10.1002/ajh.24073.

11.

Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases.

Leclerc M, Suarez F, Noël MP, Vekhoff A, Troussard X, Claisse JF, Thieblemont C, Maloisel F, Beguin Y, Tamburini J, Barbe C, Delmer A.

Ann Hematol. 2015 Jan;94(1):89-95. doi: 10.1007/s00277-014-2175-0. Epub 2014 Sep 7.

12.

BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study.

Michallet M, Luporsi E, Soubeyran P, Amar NA, Boulanger V, Carreiro M, Dourthe LM, Labourey JL, Lepille D, Maloisel F, Mouysset JL, Nahon S, Narciso B, Nouyrigat P, Radji R, Sakek N, Albrand H; ORHEO study group.

BMC Cancer. 2014 Jul 10;14:503. doi: 10.1186/1471-2407-14-503. Erratum in: BMC Cancer. 2014;14:720.

13.

Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.

Cornet E, Delmer A, Feugier P, Garnache-Ottou F, Ghez D, Leblond V, Levy V, Maloisel F, Re D, Zini JM, Troussard X; French Society of Haematology.

Ann Hematol. 2014 Dec;93(12):1977-83. doi: 10.1007/s00277-014-2140-y. Epub 2014 Jul 5.

14.

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.

San-Miguel J, Bladé J, Shpilberg O, Grosicki S, Maloisel F, Min CK, Polo Zarzuela M, Robak T, Prasad SV, Tee Goh Y, Laubach J, Spencer A, Mateos MV, Palumbo A, Puchalski T, Reddy M, Uhlar C, Qin X, van de Velde H, Xie H, Orlowski RZ.

Blood. 2014 Jun 26;123(26):4136-42. doi: 10.1182/blood-2013-12-546374. Epub 2014 May 15. Erratum in: Blood. 2014 Aug 14;124(7):1201.

15.

Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.

Kamioner D, Fruehauf S, Maloisel F, Cals L, Lepretre S, Berthou C.

BMC Cancer. 2013 Nov 16;13:547. doi: 10.1186/1471-2407-13-547.

16.

MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.

Leleu X, Rodon P, Hulin C, Daley L, Dauriac C, Hacini M, Decaux O, Eisemann JC, Fitoussi O, Lioure B, Voillat L, Slama B, Al Jijakli A, Benramdane R, Chaleteix C, Costello R, Thyss A, Mathiot C, Boyle E, Maloisel F, Stoppa AM, Kolb B, Michallet M, Lamblin A, Natta P, Facon T, Elalamy I, Fermand JP, Moreau P.

Thromb Haemost. 2013 Oct;110(4):844-51. doi: 10.1160/TH13-02-0140. Epub 2013 Aug 1.

PMID:
23903204
17.

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.

Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H; Omacetaxine 202 Study Group.

Blood. 2012 Sep 27;120(13):2573-80. Epub 2012 Aug 15.

18.

Gender-related analysis of the clinical presentation, treatment response and outcome in patients with immune thrombocytopenia.

Andrès E, Mecili M, Fothergill H, Zimmer J, Vogel T, Maloisel F.

Presse Med. 2012 Sep;41(9 Pt 1):e426-31. doi: 10.1016/j.lpm.2012.02.010. Epub 2012 Mar 28.

PMID:
22459990
19.

Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.

Yakoub-Agha I, Mary JY, Hulin C, Doyen C, Marit G, Benboubker L, Voillat L, Moreau P, Berthou C, Stoppa AM, Maloisel F, Rodon P, Dib M, Pegourie B, Casassus P, Slama B, Damaj G, Zerbib R, Harousseau JL, Mohty M, Facon T; Intergroupe Francophone du Myélome (IFM).

Eur J Haematol. 2012 Mar;88(3):249-59. doi: 10.1111/j.1600-0609.2011.01729.x. Epub 2012 Jan 4.

PMID:
22023551
20.

Clinical presentation and management of drug-induced agranulocytosis.

Andrès E, Zimmer J, Mecili M, Weitten T, Alt M, Maloisel F.

Expert Rev Hematol. 2011 Apr;4(2):143-51. doi: 10.1586/ehm.11.12.

PMID:
21495924

Supplemental Content

Loading ...
Support Center